SEPOY.net
No Result
View All Result
Tuesday, June 17, 2025
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
No Result
View All Result
SEPOY.NET
No Result
View All Result
Home Health

Prostaglandin E1 could enhance the safety of ECMO

Nicholas by Nicholas
July 18, 2022
in Health
0

In case of heart and/or lung failure, an ECMO machine can be used to maintain organ function for days or even weeks. Although extracorporeal membrane oxygenation (ECMO) technology has advanced, its use can still cause fatal complications in patients. In a recent study conducted with intensive care patients at University Hospital Vienna, MedUni Vienna researchers showed that the agent prostaglandin E1 could enhance the safety of the procedure. The study was published in the prestigious “American Journal of Respiratory and Critical Care Medicine”.

READ ALSO

Aging family physician workforce challenges primary care in Ontario

Supermarket ads push junk food for toddlers and infants

In their research, the scientific team led by Thomas Staudinger from the Department of Medicine I at MedUni Vienna and University Hospital Vienna focused on prostaglandin E1 (PGE1). This is a known agent, variously used in medicine, which affects platelets and the vascular system. The researchers hypothesized that PGE1 improves the compatibility of human blood with exogenous surfaces. However, despite medical advances, the contact of blood with foreign surfaces in ECMO still poses a risk of thromboembolism. As shown in the study, those patients who received PGE1 were less likely to exhibit clotting or visible signs of bleeding. It appears promising that the agent could increase safety when ECMO is used.

Prostaglandin E1 or saline solution

The study was randomized, placebo-controlled, and double-blind in a design considered to be of particularly high scientific quality. The participants were patients with respiratory failure in two intensive care units at MedUni Vienna’s University Hospital. Participants were randomly assigned (randomized) to receive an intravenous infusion of PGE1 or saline (placebo-controlled). In addition, anticoagulation with unfractionated heparin was administered as routine therapy. Neither the patients nor the clinical team knew which substance was used, PGE1 or placebo (double-blind). In total, 24 patients received PGE1 in the study, and 24 patients received a placebo.

Immune response with dangerous consequences

ECMO is used for extracorporeal oxygenation of the blood in patients with heart and/or lung failure. The process involves withdrawing blood from a large vein using a system of tubes, artificially enriching it with oxygen via a membrane outside the body (extracorporeal), and then pumping it back into the body through another large blood vessel near the heart. The technology is now well advanced, but the problem of human blood being exposed to foreign surfaces remains a critical issue. As a result of a physiological immune response, this can lead to activation of the blood coagulation system and ultimately to the formation of a blood clot that would impede the ECMO machine and/or the vessels in the patient’s own body.

To prevent this, patients require anticoagulation. The dosage of these must be adjusted so that, on the one hand, no clots form and, on the other hand, no bleeding occurs. Finding this balance is a major challenge in the therapeutic use of ECMO.

Treatment with prostaglandin E1 could remedy this problem. However, larger-scale studies are still required to confirm its efficacy.”


Thomas Staudinger, Department of Medicine I at MedUni Vienna and University Hospital Vienna

Source:

Medical University of Vienna

Journal reference:

Buchtele, N., et al. (2022) Add-On Prostaglandin E1 in Venovenous Extracorporeal Membrane Oxygenation: A Randomized, Double-Blind, Placebo-controlled Pilot Trial. American Journal of Respiratory and Critical Care Medicine. doi.org/10.1164/rccm.202110-2359OC.

Tags: BleedingBloodCritical CareECMOHeartHospitalImmune ResponseIntensive CareMedicineMembranePlaceboRespiratory

Related Posts

Aging family physician workforce challenges primary care in Ontario
Health

Aging family physician workforce challenges primary care in Ontario

June 17, 2025
Supermarket ads push junk food for toddlers and infants
Health

Supermarket ads push junk food for toddlers and infants

June 17, 2025
Estrogen-responsive cells found to heighten gut pain in females
Health

Estrogen-responsive cells found to heighten gut pain in females

June 17, 2025
First patient treated in international clinical trial for rare muscle-weakness disease
Health

First patient treated in international clinical trial for rare muscle-weakness disease

June 16, 2025
Paternal mental health found to impact child development
Health

Paternal mental health found to impact child development

June 16, 2025
Two existing medications work effectively together in treating alcohol use disorder
Health

Two existing medications work effectively together in treating alcohol use disorder

June 16, 2025
Next Post

Most Unique Corporate Gift Ideas for Any Business

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

About

Sepoy.net is a perfect place for people who want daily updates on news related to business, technology, entertainment, health, cryptocurrency etc.

Contact: hello@sepoy.net

Major Categories

News

Business

Tech

Economy

 

Recent Posts

  • How to Enjoy and Win on the Wheres the newest Gold Pokie Host
  • Better Internet poker Real money Websites to have United states bombastic casino Professionals
  • Aristocrat Pokies Online free of charge Gamble

Pages

  • About Us
  • Contact Us
  • Disclaimer
  • DMCA
  • Home
  • Privacy Policy

© 2023 Sepoy.net

No Result
View All Result
  • Home
  • Business
  • News
  • Health
  • Tech
  • Science
  • Lifestyle
  • Travel

© 2023 Sepoy.net